Haemonetics Corporation HAE
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +49.28%
- 1 year
- +139.25%
- Open
- 120.50
- Prev close
- 119.79
- Mkt cap
- 5.44B
- Vol
- 452.86K
- Avg vol
- 725.65K
- EPS
- 2.07
- P/E
- 57.80
- Div yield
- 0.00%
More statistics
- Low
- 118.40
- High
- 120.47
- Forward P/E
- 20.72
- Beta
- 0.61
- Short ratio
- 4.81
- Inst. own
- 112.49%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 109.75
- 200-d avg
- 78.42
- 1y target
- 124.50
2Y chart
Events in this range
- Aug 7, 2025Earnings: 1.1; estimate 1.01; surprise 8.91%
- Nov 6, 2025Earnings: 1.27; estimate 1.12; surprise 13.39%
- Feb 5, 2026Earnings: 1.31; estimate 1.27; surprise 3.15%
- May 7, 2026Earnings: 1.29; estimate 1.28; surprise 0.78%
- Aug 6, 2026Earnings: 1.14; estimate 1.08; surprise 5.56%
- Aug 21, 2026Rating: Baird · Outperform → Outperform
- Sep 3, 2026Rating: Raymond James · Outperform → Outperform
- Sep 17, 2026Rating: Citigroup · Neutral → Buy
- Oct 8, 2026Rating: BTIG · Buy → Buy
- Oct 9, 2026Rating: Mizuho · Outperform → Outperform
- Oct 9, 2026Rating: Barrington Research · Outperform → Outperform
Signals (63)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 22, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 8, 2026 | 3 weeks ago |
| RSI: Overbought | Oct 8, 2026 | 3 weeks ago |
| RSI: Overbought | Sep 17, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| RSI: Overbought | Aug 18, 2026 | 2 months ago |
| RSI: Overbought | Aug 12, 2026 | 2 months ago |
| RSI: Overbought | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 28, 2026 | 3 months ago |
| RSI: Overbought | Jul 28, 2026 | 3 months ago |
| MACD: Sell Signal | Jun 18, 2026 | 4 months ago |
| RSI: Overbought | Jun 4, 2026 | 5 months ago |
| RSI: Overbought | May 29, 2026 | 5 months ago |
| SMA: Bullish | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| MACD: Buy Signal | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 1, 2026 | 6 months ago |
| MACD: Sell Signal | May 1, 2026 | 6 months ago |
| SMA: Bullish | Apr 30, 2026 | 6 months ago |
| SMA: Bearish | Apr 28, 2026 | 6 months ago |
| SMA: Bullish | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| SMA: Bullish | Apr 14, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 6, 2026 | 6 months ago |
| RSI: Oversold | Mar 24, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 16, 2026 | 7 months ago |
| MACD: Buy Signal | Feb 19, 2026 | 8 months ago |
| SMA: Bearish | Feb 2, 2026 | 9 months ago |
| SMA: Bullish | Jan 30, 2026 | 9 months ago |
| SMA: Bearish | Jan 28, 2026 | 9 months ago |
| RSI: Oversold | Jan 20, 2026 | 9 months ago |
| SMA: Bearish | Jan 14, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 5, 2025 | 11 months ago |
| SMA: Bullish | Nov 6, 2025 | 12 months ago |
| SMA: Bullish | Nov 6, 2025 | 12 months ago |
| RSI: Overbought | Nov 6, 2025 | 12 months ago |
| RSI: Oversold | Sep 25, 2025 | 1 year ago |
| RSI: Oversold | Sep 12, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 26, 2025 | 1 year ago |
| SMA: Bearish | Aug 7, 2025 | 1 year ago |
| RSI: Oversold | Aug 7, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 15, 2025 | 1 year ago |
| RSI: Overbought | Jul 10, 2025 | 1 year ago |
| RSI: Overbought | Jul 1, 2025 | 1 year ago |
| RSI: Overbought | Jun 26, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 24, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 16, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 5, 2025 | 1 year ago |
| MACD: Sell Signal | May 22, 2025 | 1 year ago |
| RSI: Overbought | May 12, 2025 | 1 year ago |
| SMA: Bullish | May 6, 2025 | 1 year ago |
| SMA: Bearish | May 5, 2025 | 1 year ago |
| SMA: Bullish | May 2, 2025 | 1 year ago |
| SMA: Bearish | Apr 30, 2025 | 1 year ago |
| SMA: Bullish | Apr 29, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 23, 2025 | 1 year ago |
| RSI: Oversold | Apr 8, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 21, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 19, 2025 | 1 year ago |
| RSI: Oversold | Feb 7, 2025 | 1 year ago |
| RSI: Oversold | Feb 3, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 16, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 3, 2025 | 1 year ago |
Key statistics
- Market cap
- 5.45B
- Enterprise value
- 6.40B
- Trailing P/E
- 57.83
- Forward P/E
- 20.72
- PEG ratio
- 1.90
- Price / sales
- 4.03
- Price / book
- 6.50
- EPS (TTM)
- 2.07
- Beta
- 0.61
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 7.12%
- Revenue (TTM)
- 1.35B
- Revenue growth
- 5.60%
- Free cash flow
- 312.84M
- Total cash
- 224.52M
- Total debt
- 1.17B
- Return on equity
- 11.20%
- Shares outstanding
- 45.50M
- Short % of float
- 8.82%
- 50-day average
- 109.75
- 200-day average
- 78.42
Analyst view
Consensus: buy
- Target (low)
- 86.00
- Target (mean)
- 124.50
- Target (high)
- 142.00
- Strong buy4
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 1.29.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 27, 2026 | 1.29 | — | — | — |
| Aug 6, 2026 | Jun 27, 2026 | 1.08 | 1.14 | +0.06 | +5.56% |
| May 7, 2026 | Mar 28, 2026 | 1.28 | 1.29 | +0.01 | +0.78% |
| Feb 5, 2026 | Dec 27, 2025 | 1.27 | 1.31 | +0.04 | +3.15% |
| Nov 6, 2025 | Sep 27, 2025 | 1.12 | 1.27 | +0.15 | +13.39% |
| Aug 7, 2025 | Jun 28, 2025 | 1.01 | 1.10 | +0.09 | +8.91% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2026 | Barrington Research | main | Outperform | Outperform |
| Oct 9, 2026 | Mizuho | main | Outperform | Outperform |
| Oct 8, 2026 | BTIG | main | Buy | Buy |
| Sep 17, 2026 | Citigroup | up | Neutral | Buy |
| Sep 3, 2026 | Raymond James | main | Outperform | Outperform |
| Aug 21, 2026 | Baird | main | Outperform | Outperform |
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- haemonetics.com
News
- GEHC vs. HAE: Which Stock Is the Better Value Option?
- Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts
- All You Need to Know About Haemonetics (HAE) Rating Upgrade to Buy
- Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update
- Haemonetics Receives FDA Approval For PerQseal Elite Vascular Closure System For Large-Bore Arterial Procedures
- Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140
- Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140
- BTIG Maintains Buy on Haemonetics, Raises Price Target to $130
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Haemonetics Stock Hits 52-Week High - Here's Why
Your note
Sign in to keep a note on HAE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABERNATHY ROBERT E | Director | Stock Award(Grant) | Jul 23, 2026 | 27,519 |
| BASIL MICHELLE L | General Counsel | Stock Award(Grant) | May 14, 2026 | 68,829 |
| DARECCA JAMES | Chief Financial Officer | Stock Award(Grant) | May 14, 2026 | 54,444 |
| DOCKENDORFF CHARLES J | Director | Stock Award(Grant) | Jul 23, 2025 | 25,041 |
| GALVIN ROY | Officer | Stock Award(Grant) | May 14, 2026 | 39,882 |
| KROLL MARK W | Director | Stock Award(Grant) | Jul 23, 2026 | 27,295 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.99% | 5,909,258 | 707.33M | Jun 29, 2026 |
| Neuberger Berman Group, LLC | 9.19% | 4,179,443 | 500.28M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.60% | 2,546,394 | 304.80M | Jun 29, 2026 |
| AQR Capital Management, LLC | 4.98% | 2,266,489 | 271.30M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.53% | 2,059,578 | 246.53M | Jun 29, 2026 |
| Ariel Investments, LLC | 4.53% | 2,060,966 | 246.70M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 1,621,301 | 194.07M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 1,441,654 | 172.56M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.62% | 1,194,166 | 142.94M | Sep 29, 2026 |
| NEUBERGER BERMAN EQUITY FUNDS-Neuberger Genesis Fund | 2.59% | 1,179,168 | 141.15M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 1,041,356 | 124.65M | Jun 29, 2026 |
| Touchstone Strategic TRT-Touchstone Strategic TRT-Touchstone Small Com | 1.35% | 614,824 | 73.59M | Jun 29, 2026 |